Floatz logo

METOCLOPRAMIDE

Stroke Disorder

Shaheed Zulfiqar Ali Bhutto Medical UniversitySmall moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

128 Active assets in the Stroke Disorder cohort.

Asset / SponsorPhaseRating
Aggrenox
Boehringer Ingelheim
Phase 4BBB
INCOBOTULINUMTOXINA
Parc de Salut Mar
Phase 4BBB
ATENOLOL
Northern California Institute of Research and Education
Phase 4BBB
Tenecteplase
Assistance Publique - Hôpitaux de Paris
Phase 4BBB
Dextromethorphan
University of Florida
Phase 4BBB

View all 50 →

Same molecule, other indications

METOCLOPRAMIDE is also rated in:

migraine disorderActive
BB
Indicative · Phase 4
71 / 100
View asset →
migraine without auraDormant
BB
Indicative · Phase 4
69 / 100
View asset →
aspiration pneumoniaActive
BB
Indicative · Phase 4
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →